您现在的位置: 论文网 >> 医药学论文 >> 药学论文 >> 阿司匹林抵抗的产生机制与防治策略论文

阿司匹林抵抗的产生机制与防治策略

作者:张仁岗,张军平
出处:论文网
时间:2007-09-11

  4 展望

  对于AR,还存在很多未知因素,其复杂性和群体特征性是并存的,需进一步深入研究。在研究AR及临床防治AR时,应在考虑其复杂性的基础上,兼顾群体差别性,区别地辨证地对待这种现象,针对不同的群体制定不同的研究方案,为不同的个体制定更有效的治疗策略,使个体化治疗得到更高层次的体现。比如,我们可根据挟杂危险因素的不同来划分不同的群体,通过研究这些不同群体中AR产生的机理,相应地揭示其可能的群体特征。目前,关于AR的研究还不够全面,不够系统,也存在很多争议,结合中医中药,针对不同的群体进行AR的产生机理及防治方面的研究是一条值得探索之路。

【参考文献】
   1 Sztriha LK, Sas K, Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci. 2005; (229-230): 163-169.

  2 Weber ZZ, Zimmermann KC, Meyer-Kirchrath J, et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet. 1999; 353: 900.

  3 Weber AA, Przytulski B, Schumacher M, et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients under-going coronary artery bypass grafting. Br J Haematol. 2002; 117(2): 424-426.

  4 Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxyge-nase-2 expression is induced during human megakaryo-poiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA. 2002; 99: 7634-7639.

  5 Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005; 142(3): 157-164.

  6 Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005; 165(9): 978-984.

  7 Nurtjahja-Tjendraputra E, Ammit AJ, Roufogalis BD, et al. Effective anti-platelet and COX-1 enzyme inhibi-tors from pungent constituents of ginger. Thromb Res. 2003; 111(4-5): 259-265.

  8 Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345(25): 1809-1817.

  9 Cryer B, Berlin RG, Cooper SA, et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther. 2005; 27(2): 185-191.

  10 Kong DF. Aspirin in cardiovascular disorders. What is the optimum dose? Am J Cardiovasc Drugs. 2004; 4(3): 151-158.

  11 Helgason CM, Tortorice KL, Winkler SR, et al. Aspi-rin response and failure in cerebral infarction. Stroke. 1993; 24(3): 345-350.

  12 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71-86.

  13 Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin inhealthy volunteers. Stroke. 2006; 37(8): 2153-2158

  14 Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 2002; 107(1-2): 45-49.

  15 Christiaens L, Macchi L, Herpin D, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res. 2002; 108(2-3): 115-119.

  16 Mattiasson I, Lethagen S, Hillarp A. Increased sensi-tivity to ADP-aggregation in aspirin treated patients with recurrent ischemic stroke? Int Angiol. 2003; 22(3): 239-242.

  17 Payne DA, Jones CI, Hayes PD, et al. Platelet inhibi-tion by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance? Thromb Haemost. 2004; 92(1): 89-96.

  18 Mirkhel A, Peyster E, Sundeen J, et al. Frequency of aspirin resistance in a community hospital. Am J Cardi-ol. 2006; 98(5): 577-579.

  19 Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol. 2003; 42(6): 1115-1119.

  20 Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001; 88(3): 230-235.

  21 Jagroop IA, Mikhailidis DP. Doxazosin, an alpha1- adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Hum Hypertens. 2001; 15(3): 203-207.

上一页 [1] [2]

论文搜索
关键字:阿司匹林 药品
最新药学论文
高职高专药学专业实习―就业一体化模式探索
基于职业岗位迁移能力培养的药学专业综合实
高职药学专业实习就业一体化模式的探索与实
怀玉山三叶青的生药学研究
药学干预对肿瘤患者丙氨酰谷氨酰胺使用的效
医院临床药学服务的定位与改进措施分析
我校临床药学专业研究生教育现状研究与探讨
药学类研究生全英文课程《天然药物导论》的
连续性药学监护改善1例VTE患者抗凝效果
药学指导在高血压合并2型糖尿病老年患者中的
热门药学论文
浅谈药品不良反应与安全用药
抗感冒药的不良反应
抗生素的药物不良反应
中药不良反应分析
阿司匹林抵抗的产生机制与防治策略
半夏与水半夏的鉴别特征
药学监护
抗心律失常药物的近代认识
我国药品市场发展中存在的问题与对策研究
抗结核药物的研究进展